©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2017; 9(4): 166-175
Published online Apr 15, 2017. doi: 10.4251/wjgo.v9.i4.166
Published online Apr 15, 2017. doi: 10.4251/wjgo.v9.i4.166
Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy
Keishi Yamashita, Akira Ema, Kei Hosoda, Hiroaki Mieno, Hiromitsu Moriya, Natsuya Katada, Masahiko Watanabe, Department of Gastrointestinal Surgery, Kitasato University School of Medicine, Kanagawa 252-0374, Japan
Author contributions: All authors contributed to the manuscript.
Institutional review board statement: This study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Kitasato University School of Medicine. The requirement for informed consent was waived because of the retrospective study design.
Conflict-of-interest statement: There is no conflict of interest in this study.
Data sharing statement: No additional data are available.
Correspondence to: Keishi Yamashita, MD, PhD, FACS, Lecturer, Department of Gastrointestinal Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan. keishi23@med.kitasato-u.ac.jp
Telephone: +81-42-7788111 Fax: +81-42-7789556
Received: October 17, 2016
Peer-review started: October 19, 2016
First decision: November 22, 2016
Revised: December 7, 2016
Accepted: February 8, 2017
Article in press: February 10, 2017
Published online: April 15, 2017
Processing time: 174 Days and 16.7 Hours
Peer-review started: October 19, 2016
First decision: November 22, 2016
Revised: December 7, 2016
Accepted: February 8, 2017
Article in press: February 10, 2017
Published online: April 15, 2017
Processing time: 174 Days and 16.7 Hours
Core Tip
Core tip: In this study, we for the first time clarify the clinicopathological relevance of the macroscopic high risk patients with pathological stage II/III gastric cancer who underwent curative surgery with postoperative S1 adjuvant chemotherapy in Japan.